

Cord blood continues to be a valuable resource for families.

As of the end of 2024, over 600 families had used their cord blood stored with ViaCord for a stem cell transplant or regenerative medicine indication.

Stem Cell Transplants 48%

Cord blood has been a reliable, effective, and life-saving source of stem cells in transplants for over 30 years. Hematopoietic Stem Cells (HSCs) collected from cord blood can be used in stem cell transplants for nearly 80 conditions to regenerate a healthy blood and immune system. Although most conditions are inherited genetic diseases, likely requiring a sibling or donor cells, a child's own cord blood may be used in certain cases, such as neuroblastoma.

Regenerative Medicine Indications 52%


Regenerative Medicine aims to harness the body's natural healing mechanisms by using living, healthy cells to potentially stimulate, regenerate, replace, or repair damaged cells, tissues, or organs, ultimately restoring normal function. "Regenerative Medicine Indication" is the specific disease, condition, or injury that these therapies are being studied to treat. It's important to remember that while regenerative medicine is a rapidly advancing and exciting field, not all proposed indications have FDA approval or are considered standard medical care yet. Research and clinical trials are ongoing for many potential applications.

- Hemoglobinopathy 49%
- Oncology 24%
- Bone Marrow Failure 18%
- Immunodeficiency 7%
- Metabolic Disorder 2%
- 299 Releases

 321 Releases
- Brain Injury/Dysfunction 97.5%
- Auto Immune 1.8%
- Other 0.7%

Cord Blood Recipient

Using one's own stem cells (autologous) versus a donor source of stem cells (allogeneic) is determined by specific and multiple factors, including the patient's condition and the availability of a compatible donor (match) adequate to be considered for clinical use. Ultimately, the treating physician will make the final decision.



- Self 44% (Autologous)
- Donor/Sibling 56% (Allogenic)

Samples Age Range

Samples in storage from 7 days to 19 years have been released for use.



7 DAYS

Sibling (Allogeneic)
Transplant for Cancer
Acute Myeloid Leukemia

19 YEARS

Sibling (Allogeneic) Infusion for Brain Injury Cerebral Palsy

